Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

2.30
-0.0500-2.13%
Post-market: 2.300.00000.00%16:02 EDT
Volume:208.20K
Turnover:486.61K
Market Cap:99.29M
PE:-0.58
High:2.39
Open:2.32
Low:2.29
Close:2.35
Loading ...

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT Newswires Live
·
14 Dec 2024

Kyverna Therapeutics announces senior leadership appointments

TIPRANKS
·
14 Dec 2024

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

THOMSON REUTERS
·
14 Dec 2024

Press Release: Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

Dow Jones
·
14 Dec 2024

Kyverna shares remain ‘significantly under-valued,’ says JPMorgan

TIPRANKS
·
03 Dec 2024

Optimistic Buy Rating for Kyverna Therapeutics Driven by Promising KYV-101 Data and Pipeline Expansion

TIPRANKS
·
21 Nov 2024

Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $6 From $7

THOMSON REUTERS
·
20 Nov 2024

Morgan Stanley’s Positive Outlook on Kyverna Therapeutics’ KYV-101 for Lupus Nephritis

TIPRANKS
·
20 Nov 2024

Analysts Offer Insights on NA Companies: Viking Holdings Ltd (VIK), Kyverna Therapeutics, Inc. (KYTX) and Amer Sports, Inc. (AS)

TIPRANKS
·
20 Nov 2024

institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop

Simply Wall St.
·
17 Nov 2024

Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
16 Nov 2024

Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo

TIPRANKS
·
15 Nov 2024

Kyverna Therapeutics, Inc. : Wells Fargo Cuts Target Price to $24 From $44

THOMSON REUTERS
·
15 Nov 2024

Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs

TIPRANKS
·
15 Nov 2024

Kyverna Therapeutics anounces patient data on KYV-101

TIPRANKS
·
14 Nov 2024

Kyverna Therapeutics Inc - Kyv-101 Demonstrates Robust Safety and Tolerability

THOMSON REUTERS
·
14 Nov 2024